The results of this study suggest that there are mood changes associated with deep brain stimulation of the subthalamic nucleus (STN) and the globus pallidus interna (GPi). Further, optimal placement of electrodes in both STN and GPi seems to result in overall improvement in mood and is associated with a lower incidence of adverse mood effects than stimulation outside the optimal site. Preliminary data from this study, however, suggest that slight movement dorsal or ventral to the site of optimal motor performance may be associated with more adverse changes in mood with STN stimulation than with GPi stimulation.
- deep brain stimulation
- globus pallidus interna
- subthalamic nucleus
Statistics from Altmetric.com
Deep brain stimulation (DBS) of both the subthalamic nucleus (STN) and the globus pallidus interna (GPi) has been shown to be effective in the treatment of the cardinal motor signs of Parkinson’s disease (tremor, rigidity, and bradykinesia).1,2 Many reports suggest more robust improvements in the motor scores of the unified Parkinson’s disease rating scale (UPDRS) with STN DBS, and an ability to reduce antiparkinsonian drug treatment with STN DBS but not GPi DBS.1,2 Consequently the subthalamic nucleus has become the preferred target at most centres. There is, however, increasing evidence that STN DBS may be associated with a higher incidence of adverse changes in mood compared with GPi DBS.3,4,5,6,7,8,9,10,11,12 Mood is one factor that significantly influences the quality of life, and thus the characterisation of mood changes resulting from stimulation of both STN and GPi will be important in choosing the optimal target for patients undergoing DBS. To further characterise the mood changes that occur in STN and GPi DBS, we assessed mood changes associated with stimulation in nine patients who underwent either form of treatment.
We studied nine patients with idiopathic Parkinson’s disease. They were all examined by a movement disorders specialist and had at least two cardinal motor signs including akinesia/bradykinesia, rigidity, or tremor, and three supporting signs which could include unilateral onset, rest tremor, progressive disorder, asymmetry, excellent response to levodopa, dyskinesia, levodopa response for five years, and clinical course of 10 years. Five had unilateral STN DBS and four had unilateral GPi DBS (table 1).
All were assessed on the UPDRS III motor scale (off drug treatment) and the visual analogue mood scale (VAMS)13 under five randomised conditions: off stimulation and during monopolar stimulation with each of four contacts (Medtronic 3387 DBS electrode). The UPDRS III was administered five minutes after each change of testing condition (table 2). The VAMS was administered 30 minutes after the change of testing condition. The mood scale included subscores for each of eight categories: afraid, confused, sad, angry, energetic, tired, happy, and tense.
Patient raw scores on the VAMS were converted to T scores using normative data provided in the test manual. Patients were screened with the Mattis dementia rating scale, the Hamilton depression scale, the Hamilton anxiety scale, and the geriatric depression scale to exclude cognitive dysfunction or active psychiatric disease before entry into the study.
Inclusion criteria for the study included an age between 30 and 75 years, a diagnosis of idiopathic Parkinson’s disease, a clear response to levodopa, intractable disabling motor fluctuations, dyskinesias, or freezing episodes, a Mattis dementia rating scale score of more than 130, and no significant active psychiatric disorder. All patients were rated Hoehn and Yahr grade III or greater in the “off condition.” All patients underwent the same surgical technique (multiple pass microelectrode recording, macrostimulation, target verification by postoperative magnetic resonance imaging), and signed their informed consent before participating in the study.
Effects of DBS on mood when stimulating at the site of optimal motor improvement
Stimulation at the site of optimal motor benefit (determined by the UPDRS III motor score) was associated with changes in mood in patients in both DBS groups. Change in mood was identified as a minimum of one standard deviation change in at least one VAMS subscale (table 3). For STN patients, four of five showed improvement on at least one subscale with optimal stimulation, and three showed improvement on at least two subscales. Two patients showed decline, each on only one subscale. For GPi patients, two of four showed improvement of at least 2 SD on four VAMS subscales when on optimised stimulation. Only one patient showed worsening, and this occurred on only one subscale (tense).
Effects of DBS on mood when stimulating dorsal or ventral to the site of optimal motor benefit
Stimulation one contact dorsal to the optimal contact led to improvement in at least two subscales in two of the five STN patients and two of the four GPi patients. Stimulation dorsally led to a decline in at least two subscales in two of the five STN patients and one of the four GPi patients. Stimulation ventrally led to no improvements on at least two subscales in each of the STN patients, and to improvement in at least two subscales in one of the four GPi patients. Stimulation one contact ventral to the optimal contact led to a decline in at least two subscales in two of the five STN patients, and two of the four GPi patients. Overall, slightly more worsening was seen in the number of subscales changed for the STN group (five subscales dorsally, seven subscales ventrally) than for the GPi group (three subscales dorsally, five subscales ventrally), although the STN group had one more patient than the GPi group (table 4). The magnitude of change in scales that worsened was slightly greater in the STN when compared with the GPi group, but the magnitude of change in scales that improved was better in the GPi group.
The results of this study suggest that there are mood changes associated with deep brain stimulation in the STN and GPi. Stimulation at optimally placed electrodes in both the STN and the GPi may result in some improvement in mood when compared with no stimulation. Stimulation dorsal or ventral to the optimal electrode may also produce mood changes. Owing to the small number of patients studied in this report, a statistically powered comparison of STN to GPi DBS cannot be done and will require a larger study. Additionally, changes measured at five minutes may not reflect maximal change in the motor scores. The timing of evaluations will require further study.
Despite a lack of randomised controlled studies to compare the relative effects of stimulation of GPi and STN, most centres currently choose stimulation of STN over GPi for the treatment of advanced Parkinson’s disease. This choice is based on the reported greater improvement in motor scores with STN stimulation, as well as the ability to reduce antiparkinsonian drugs, an advantage not reported with GPi stimulation.1,2 More recently, reports of specific mood side effects induced by STN DBS3–4,6,14 have raised questions about the use of this target, particularly in the elderly. Although changes in mood have been shown to occur during DBS in both the subthalamic nucleus and the globus pallidus,3,4,5,6,7,8,9,10,11,12 there are only a few anecdotal reports and case studies describing these findings. Mood changes reported in previous studies of STN DBS include depression,3,9,12 pseudobulbar crying,8 mirthful laughter,4 mania,11 aggression,10 personality disorder,9 apathy,7 anxiety,7,9 and irritability.7 Additionally, the issue of an increased risk of suicide attempts with STN DBS has been raised recently.12,15 GPi DBS has not been reported to have as many mood side effects.2,5,6 Apathy and abulia have been described in one patient,6 and mania16 in another.
Changes in mood and cognition during stimulation of the STN and GPi may be caused by spread of current to non-motor (associative and limbic) portions of the STN and GPi, as well as spread to adjacent pathways mediating non-motor functions. Both the STN and GPi have motor and non-motor areas that project to cortical areas associated with motor, mood, and cognitive function, and stimulation of both nuclei has been reported to be associated with changes in mood and cognition to a varying degree. The STN (158 mm3) is a smaller nucleus than the GPi (478 mm3), and there are motor, associative, and limbic circuits as well as multiple fibre pathways (medial forebrain bundle, zona incerta, lateral hypothalamus) subserving associative and limbic functions located in a compact area within and adjacent to the STN. A larger sample size than in our pilot study will be needed to answer the question of whether there are more mood and cognitive side effects with STN stimulation compared with GPi stimulation. Additionally, as shown by our small study, correctly placed leads in both the STN and the GPi are in some cases associated with positive effects on mood.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.